Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers

Colleen M. Niswender, Carrie K. Jones, Xin Lin, Michael Bubser, Analisa Thompson Gray, Anna L. Blobaum, Darren W. Engers, Alice L. Rodriguez, Matthew T. Loch, J. Scott Daniels, Craig W. Lindsley, Corey R. Hopkins, Jonathan A. Javitch, P. Jeffrey Conn

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Metabotropic glutamate receptor 4 (mGlu4) is emerging as a potential therapeutic target for numerous central nervous system indications, including Parkinson's disease (PD). As the glutamate binding sites among the eight mGlu receptors are highly conserved, modulation of receptor activity via allosteric sites within the receptor transmembrane domains using positive and negative allosteric modulators (PAMs and NAMs, respectively) has become a common strategy. We and others have used PAMs targeting mGlu4 to show that potentiation of receptor signaling induces antiparkinsonian activity in a variety of PD animal models, including haloperidol-induced catalepsy and 6-hydroxydopamine-induced lesion. Recently, mGlu4 has been reported to form heteromeric complexes with other mGlu receptor subtypes, such as mGlu2, and the resulting heteromer exhibits a distinct pharmacological profile in response to allosteric modulators. For example, some mGlu4 PAMs do not appear to potentiate glutamate activity when mGlu2 and mGlu4 are coexpressed, whereas other compounds potentiate mGlu4 responses regardless of mGlu2 coexpression. We report here the discovery and characterization of VU0418506, a novel mGlu4 PAM with activity in rodent PD models. Using pharmacological approaches and Complemented Donor-Acceptor resonance energy transfer (CODA-RET) technology, we find that VU0418506 does not potentiate agonist-induced activity when mGlu2 and mGlu4 are heterodimerized, suggesting that the antiparkinsonian action of mGlu4 PAMs can be induced by compounds without activity at mGlu2/4 heteromers.

Original languageEnglish (US)
Pages (from-to)1201-1211
Number of pages11
JournalACS Chemical Neuroscience
Volume7
Issue number9
DOIs
StatePublished - Sep 21 2016

    Fingerprint

Keywords

  • Allosteric modulator
  • Parkinson's disease
  • metabotropic glutamate receptor

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Niswender, C. M., Jones, C. K., Lin, X., Bubser, M., Thompson Gray, A., Blobaum, A. L., Engers, D. W., Rodriguez, A. L., Loch, M. T., Daniels, J. S., Lindsley, C. W., Hopkins, C. R., Javitch, J. A., & Conn, P. J. (2016). Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. ACS Chemical Neuroscience, 7(9), 1201-1211. https://doi.org/10.1021/acschemneuro.6b00036